Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000170872 | SCV000223427 | likely benign | not provided | 2021-07-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000618110 | SCV000737504 | likely benign | Cardiovascular phenotype | 2020-12-10 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV001085407 | SCV000767972 | likely benign | Brugada syndrome 4 | 2024-01-08 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002281992 | SCV002571833 | likely benign | not specified | 2022-08-06 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001085407 | SCV004564848 | uncertain significance | Brugada syndrome 4 | 2023-11-08 | criteria provided, single submitter | clinical testing | The CACNB2 c.1430G>A; p.Arg477His variant (rs184280124), to our knowledge, is not reported in the medical literature but is reported in ClinVar (Variation ID: 190729). This variant is found in the Latino population with an allele frequency of 0.14% (49/34,420 alleles) in the Genome Aggregation Database. The arginine at codon 477 is moderately conserved considering 12 species and computational analyses (SIFT: tolerated, PolyPhen-2: probably damaging) predict conflicting effects of this variant on protein structure/function. Due to limited information, the clinical significance of this variant is uncertain at this time. |